利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.032 seconds)

    E. coli extract for protein synthesis
    1.
    发明申请
    E. coli extract for protein synthesis 失效
    大肠杆菌提取物用于蛋白质合成

    公开(公告)号：US20020034559A1

    公开(公告)日：2002-03-21

    申请号：US09848449

    申请日：2001-05-03

    Inventor： Yuping Ambuel ,  Thomas R. Van Oosbree ,  Mark R. McCormick ,  Robert C. Mierendorf

    IPC: A61K035/66 ,  A61K035/68 ,  C12P021/06 ,  A01N063/02

    CPC classification number: C07K14/245 ,  C12P21/02

    Abstract: There is now a market for kits containing the necessary components for performing protein synthesis reactions using template DNA of the experimenter. One category of existing system for performing protein synthesis reactions is based on an S-30 extract from the bacteria E. coli. It is disclosed here that a simple fractionation process can dramatically improve the performance of an S-30 prokaryotic protein synthesis reaction mixture. In one embodiment, the fractionation is a simple freezing and thawing of an S-30 extract combined with a supplemental mix, followed by centrifugation. The resulting fractionated S-30 reaction mixture yields more full-length target protein and less non-full length or non-target protein than possible using prior art S-30 systems.

    Abstract translation: 现在有一个包含使用实验者的模板DNA进行蛋白质合成反应的必要组分的试剂盒的市场。 用于进行蛋白质合成反应的现有系统的一个类别是基于来自细菌大肠杆菌的S-30提取物。 这里公开了简单的分级方法可以显着改善S-30原核生物蛋白质合成反应混合物的性能。 在一个实施方案中，分馏是与补充混合物组合的S-30提取物的简单冷冻和解冻，然后离心。 所得到的分级的S-30反应混合物比现有技术的S-30系统产生更多的全长靶蛋白和较少的非全长或非靶蛋白。

    Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom
    2.
    发明申请
    Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom 审中-公开
    来自生物体的细菌分离物至少部分地通过其皮肤和由其衍生的生物活性提取物

    公开(公告)号：US20030072829A1

    公开(公告)日：2003-04-17

    申请号：US10037881

    申请日：2002-01-04

    Inventor： Richard M. Austin JR.

    IPC: A61K035/68

    CPC classification number: A61K35/74 ,  A61K35/744 ,  C12N1/20 ,  C12P1/04 ,  C12Q1/04 ,  C12Q1/18 ,  C12R1/01 ,  G01N33/56911 ,  G01N33/56961 ,  G01N33/56988 ,  G01N2333/4606

    Abstract: Extracts including a biologically active compound or combination of compounds derived from microorganisms isolated from mucus-producing organisms that respire at least partially through their skin. Rod-shaped bacteria isolated from the skin of salamanders and frogs are found to produce compound(s) which have antiviral, antitumor, antibacterial and antifungal properties. These compound(s) have an inhibitory effect on opportunistic human pathogens, including Candida sp., Microsporum sp., Staphylococcus sp., Pseudomonas sp., Escherichia sp, and Enterococcus sp, as well as on HIV strains and tumor cell lines.

    Abstract translation: 提取物包括生物活性化合物或衍生自分离自至少部分通过其皮肤产生粘液的生物体的微生物的化合物的组合。 发现从蝾螈和青蛙皮肤分离的棒状细菌产生具有抗病毒，抗肿瘤，抗菌和抗真菌性质的化合物。 这些化合物对机体性人类病原体具有抑制作用，包括假丝酵母属，微孢子菌属，葡萄球菌属，假单胞菌属，埃希氏菌属，肠球菌属，以及HIV菌株和肿瘤细胞系。

    Topical cosmetic composition
    4.
    发明申请
    Topical cosmetic composition 有权
    局部化妆品组成

    公开(公告)号：US20020168388A1

    公开(公告)日：2002-11-14

    申请号：US10013003

    申请日：2001-11-05

    Inventor： Stefan Borchert ,  Rolf-Dieter Petersen

    IPC: A61K035/74 ,  A61K035/76 ,  A61K035/68 ,  A61K035/66

    CPC classification number: A61K8/97 ,  A61K8/99 ,  A61Q17/04 ,  A61Q19/08

    Abstract: The invention relates to cosmetic compositions for topical application for counteracting UV radiation induced skin damage comprising as active substances a first component which comprises inactivated bacteria selected from the group consisting of the genus Bifidobacterium, Actinomycetaceae, Propionimycetaceae, Lactobacillaceae and Coryneform bacteria and a second component which comprises an extract of plant extracellular matrix. Preferably, the plant extracellular matrix is selected from the group consisting of glycoproteins, carbohydrate polymers and arabinogalactan proteins. Processes for using the cosmetic compositions are also described.

    Abstract translation: 本发明涉及用于抵抗UV辐射诱导的皮肤损伤的局部应用的化妆品组合物，其包含作为活性物质的第一组分，其包含选自双歧杆菌属，放线菌科，丙酸杆菌科，乳杆菌科和棒状杆菌属细菌的灭活细菌，第二组分 包括植物细胞外基质的提取物。 优选地，植物细胞外基质选自糖蛋白，碳水化合物聚合物和阿拉伯半乳聚糖蛋白。 还描述了使用化妆品组合物的方法。

    Method of inhibiting tumor necrosis factor
    5.
    发明申请
    Method of inhibiting tumor necrosis factor 审中-公开
    抑制肿瘤坏死因子的方法

    公开(公告)号：US20020031563A1

    公开(公告)日：2002-03-14

    申请号：US09758296

    申请日：2001-01-10

    Inventor： Thomas W. Hodge

    IPC: A61K035/68

    CPC classification number: A61K31/704 ,  A61K31/09 ,  A61K31/22 ,  A61K31/34 ,  A61K31/365 ,  A61K31/70 ,  A61K35/28 ,  A61K36/254 ,  A61K2300/00

    Abstract: The invention provides a method of inhibiting TNF comprising administering a TNF-inhibiting amount of an extract of Eleutherococcus senticosus maxim to a subject. Also, the present invention provides a method inhibiting TNF in a cell comprising administering to the cell a TNF inhibiting amount of an extract from Eleutherococcus senticosus maxim. Finally, the invention provides a method of treating a TNF mediated disorder in a subject, comprising administering a therapeutic amount of an extract of Eleutherococcus senticosus maxim to the subject.

    Abstract translation: 本发明提供一种抑制TNF的方法，包括向受试者施用TNF-抑制量的Eleutherococcus senticosus maxim的提取物。 此外，本发明提供了抑制细胞中TNF的方法，包括向细胞施用TNF抑制量的来自Eleutherococcus senticosus maxim的提取物。 最后，本发明提供一种治疗受试者中TNF介导的病症的方法，其包括向受试者施用治疗量的埃氏弧菌提取物。

    Kefir extract as anti-cancer agent
    6.
    发明申请
    Kefir extract as anti-cancer agent 审中-公开
    Kefir提取物作为抗癌剂

    公开(公告)号：US20040033282A1

    公开(公告)日：2004-02-19

    申请号：US10311504

    申请日：2003-07-14

    Inventor： Stan Kubow ,  Laurie Hing Man Chan ,  Chujian Chen ,  Maryam Fotouhinia

    IPC: A61K035/68

    CPC classification number: A61K35/20

    Abstract: The present invention relates to an anti-cancer composition having anti-proliferative and/or inhibitory effects specifically targeted at malignant cells, which comprises a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir in association with a pharmaceutically acceptable carrier. The present invention also relates to a method of inhibiting proliferation of malignant cells in patient, which comprises administering an effective amount of a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir. The present invention also relates to a prophylactic composition having neutraceutical properties, which comprises a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir in association with a pharmaceutically acceptable carrier.

    Abstract translation: 本发明涉及具有特异性靶向恶性细胞的抗增殖和/或抑制作用的抗癌组合物，其包括与药学上可接受的相关联的初始发酵性发酵胃蛋白的过滤的无细菌和/或无酵母液体提取物 载体 本发明还涉及一种抑制患者恶性细胞增殖的方法，其包括施用有效量的初始发酵性胃蛋白酶的无过滤的无细菌和/或无酵母液体提取物。 本发明还涉及具有营养学性质的预防组合物，其包含与药学上可接受的载体相关联的初始发酵性发酵胃蛋白的过滤的无细菌和/或无酵母液体提取物。

Patent Agency Ranking